申请人:Pharmacia & Upjohn S.p.A.
公开号:US05965563A1
公开(公告)日:1999-10-12
Novel bicyclic condensed pyrimidine compounds having general formula (I) ##STR1## wherein X is --CH.sub.2 --, --NH--(CH.sub.2).sub.n --, --O--(CH.sub.2).sub.n -- or --S--(CH.sub.2).sub.n -- in which n is zero or 1; A is a 4,5-fused imidazole ring N-substituted by R.sub.3 which is hydrogen, C.sub.1 -C.sub.4 alkyl or benzyl, or A is a 2,3-fused pyridine ring C-substituted by R.sub.4 which is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen or NR.sub.5 R.sub.6 in which each of R.sub.5 and R.sub.6 independently is H or C.sub.1 -C.sub.4 alkyl; B is a bicyclic ring chosen from tetralin, indane and 2-oxindole; each of R.sub.1 and R.sub.2 independently is hydrogen, C.sub.1 -C.sub.4 alkyl, halogen, hydroxy, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkoxycarbonyl, nitro, cyano or CF.sub.3 ; and the pharmaceutically acceptable salts thereof.
具有通式(I)的新型双环嘧啶化合物##STR1##其中X为--CH.sub.2 --,--NH--(CH.sub.2).sub.n --,--O--(CH.sub.2).sub.n --或--S--(CH.sub.2).sub.n --,其中n为零或1;A是由R.sub.3取代的4,5-融合咪唑环N-取代基,其中R.sub.3为氢、C.sub.1-C.sub.4烷基或苄基,或A是由R.sub.4取代的2,3-融合吡啶环,其中R.sub.4为氢、C.sub.1-C.sub.4烷基、C.sub.1-C.sub.4烷氧基、卤素或NR.sub.5R.sub.6,其中R.sub.5和R.sub.6各自独立为H或C.sub.1-C.sub.4烷基;B为从四氢萘、茚和2-氧吲哚中选择的双环环;R.sub.1和R.sub.2各自独立为氢、C.sub.1-C.sub.4烷基、卤素、羟基、C.sub.1-C.sub.4烷氧基、C.sub.1-C.sub.4烷氧羰基、硝基、氰基或CF.sub.3;以及其药学上可接受的盐。